US7855190 — Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Method of Use · Assigned to Teva Womens Health Inc · Expires 2028-12-05 · 3y remaining
What this patent protects
This patent protects methods of hormonal treatment using contraceptive regimens with continuous estrogen administration.
USPTO Abstract
The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1 |
Treatment of a specific disease/condition (broad) | |
U-1 |
Treatment of a specific disease/condition (broad) |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.